Document:

Exhibit 10.2

Exhibit 10.2

CONSULTING AND NON-COMPETITION AGREEMENT

This Consulting Agreement (this “Agreement”) is entered into as of September 3, 2009 (the
“Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”),
and Dr. Robert Langer, PhD (the “Consultant”).

WHEREAS, the Company desires that the Consultant provide services to the Company as an
independent contractor; and

WHEREAS, the Consultant desires to provide such services as an independent contractor; and

NOW, THEREFORE, in consideration of the mutual representations, promises and agreements
contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and
the Consultant hereby agree as follows:

1. Term of Agreement. The Company hereby engages the Consultant as a consultant,
subject to the terms and conditions hereof, for the period commencing as of the Effective Date and
ending on the last calendar day of the month in which the first anniversary of this Agreement
occurs (the “Term”). Within thirty (30) days of the expiration of this Agreement, the Company
shall review this Agreement, and either continues and extends this Agreement, terminate this
Agreement, and/or offer the Consultant a different agreement. The Consultant will be notified of
such action before the expiration of this Agreement. This Agreement shall remain in effect until
so terminated and/ or modified by the Company. Failure of the Company to take any action within
the said thirty-day time period shall be considered as an extension of this Agreement for an
additional thirty-day period. The period during which the Consultant is performing services under
this Agreement shall be referred to herein as the “Consulting Period.”

2. Consulting Services. During the Consulting Period, the Consultant shall perform
consulting services for the Company and its subsidiaries. Such consulting services are
anticipated to include serving as the Company’s Scientific Advisor. The Consultant will devote
such business time as is necessary or desirable to accomplish his duties and responsibilities under
this Agreement.

3. Independent Contractor.

(a) The Consultant shall perform the consulting services described in Section 2 as an
independent contractor without the power to bind or represent the Company for any purpose
whatsoever. Nothing herein contained shall be construed to constitute the parties hereto as
partners or as joint ventures, or either as agent of the other, or as employer and employee. The
Consultant shall not present himself as an employee of the Company or any of its affiliates.

 

 

 

(b) The Consultant shall not be entitled to participate in any employee benefit plans
maintained by on behalf of the Company or any of its affiliates during the Consulting Period. The
Consultant hereby acknowledges his separate responsibility for all federal and state withholding
taxes, Federal Insurance Contribution Act taxes, workers’ compensation and unemployment
compensation taxes and business license fees, if applicable.

(c) Subject only to such specific limitations as are contained in this Agreement, the manner,
means, details or methods by which the Consultant performs his obligations under this Agreement
shall be solely within the discretion of the Consultant. The Company shall not have the authority
to, nor shall it, supervise, direct or control the manner, means, details or methods utilized by
the Consultant to perform his obligations under this Agreement and nothing in this Agreement shall
be construed to grant the Company any such authority.

4. Compensation.

(a) Consulting Fee. In remuneration for the consulting services to be performed under
this Agreement by the Consultant during the Consulting Period, the Consultant shall receive an
annual consulting fee equal to fifty thousand dollars ($50,000) (the “Consulting Fee”), payable no
less frequently than monthly in arrears.

5. Expenses. The Company shall pay or reimburse the Consultant for all reasonable
expenses incurred by the Consultant in connection with the performance of his services under this
Agreement including, without limitation, travel and lodging expenses, consistent with Company
expense policies following receipt of appropriate documentation; provided, however, for all periods
commencing as of the Effective Date the Company shall not provide, or reimburse the Consultant for,
the use of an automobile or membership fees or dues payable in respect of the Consultant’s members
in private clubs or professional associations or organizations.

6. Termination. During the Term, this Agreement and the Consulting Period may be
terminated at any time by the Company or the Consultant upon 30 days’ prior written notice to the
other party. In the event of the termination of this Agreement pursuant to this Section 7, the
Company’s obligations under Section 4(a) shall cease, effective on the effective date of such
termination.

 

 

 

7. Non-Competition. During the period of the Consultant’s services hereunder, the
Consultant shall not, within any state or foreign jurisdiction in which the Company or any
subsidiary of the Company is then providing services or products or marketing its services or
products (or engaged in active discussions to provide such services), or within a
50-mile radius of any such state or foreign jurisdiction, directly or indirectly own any
interest in, manage, control, participate in, consult with, render services for, or in any manner
engage in any business engaged in by the Company (unless the Board of Directors shall have
authorized such activity and the Company shall have consented thereto in writing). The term
“business engaged in by the Company” shall mean the development and commercialization of autologous
fibroblast system technology for application in, among other therapies, dermatology, surgical and
post-traumatic scarring, skin ulcers, cosmetic surgery, periodontal disease, reconstructive
dentistry, vocal chord injuries, urinary incontinence, and digestive and gastroenterological
disorders and other applications relating to the market for autologous fibroblast or UMC cells and
the five derivative cell lines: osteoblast, chondroblast, fibroblast, adipocyte, and neuroectoderm.
Investments in less than five percent of the outstanding securities of any class of a corporation
subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act
of 1934, as amended, shall not be prohibited by this Section 8.

8. Confidential Information; Non-Solicitation. The parties hereto recognize that a
major need of the Company is to preserve its specialized knowledge, trade secrets, and confidential
information. The strength and good will of the Company is derived from the specialized knowledge,
trade secrets, and confidential information generated from experience with the activities
undertaken by the Company and its subsidiaries. The disclosure of this information and knowledge
to competitors would be beneficial to them and detrimental to the Company, as would the disclosure
of information about the marketing practices, pricing practices, costs, profit margins, design
specifications, analytical techniques, and similar items of the Company and its subsidiaries. The
Consultant acknowledges that the proprietary information, observations and data obtained by him
while employed by the Company and during the Consulting Period concerning the business or affairs
of the Company are the property of the Company. By reason of his having been a senior executive of
the Company and through his providing services under this Agreement, the Consultant has or will
have access to, and has obtained or will obtain, specialized knowledge, trade secrets and
confidential information about the Company’s operations and the operations of its subsidiaries,
which operations extend throughout the United States. For purposes of this Section 9, “the
Company” shall mean the Company and each of its controlled subsidiaries. Therefore, the Consultant
hereby agrees as follows, recognizing that the Company is relying on these agreements in entering
into this Agreement:

(a) The Consultant will not use, disclose to others, or publish or otherwise make available to
any other party any inventions or any confidential business information about the affairs of the
Company, including but not limited to confidential information concerning the Company’s products.
“Confidential Information” shall include commercial or trade secrets about Company’s products,
methods, engineering designs and
standards, analytical techniques, technical information, customer information, employee
information, or financial and business records, any of which contains proprietary information
created or acquired by the Company and which information is held in confidence by Company.
Confidential Information does not include information which: (x) becomes generally available to the
public, unless said Confidential Information was disclosed in violation of a confidentiality
agreement; or (y) becomes available to the Consultant on a non-confidential basis from a source
other than the Company or its agents, provided that such source is not bound by a confidentiality
agreement with the Company.

 

 

 

(b) During the Term and for 12 months thereafter, the Consultant will not directly or
indirectly through another entity (x) induce any employee of the Company to leave the Company’s
employ (unless the Board of Directors shall have authorized such employment and the Company shall
have consented thereto in writing) or in any way interfere with the relationship between the
Company and any employee thereof or (y) tortiously interfere with the Company’s business
relationship with any customer, supplier, licensee, licensor or other business relation of the
Company.

9. Representations.

(a) The Consultant hereby represents and warrants to the Company that as of the Effective
Date: (x) the execution, delivery and performance of this Agreement by the Consultant do not and
shall not conflict with, breach, violate or cause a default under any contract, agreement,
instrument, order, judgment or decree to which the Consultant is a party or by which he is bound,
and (y) upon the execution and delivery of this Agreement by the Company, this Agreement shall be
the valid and binding obligation of the Consultant, enforceable in accordance with its terms. The
Consultant hereby acknowledges and represents that he has consulted with legal counsel regarding
his rights and obligations under this Agreement and that he fully understands the terms and
conditions contained herein.

(b) The Company hereby represents and warrants to the Consultant that (x) the execution,
delivery and performance of this Agreement by the Company do not and shall not conflict with,
breach, violate or cause a default under any contract, agreement, instrument, order, judgment or
decree to which the Company is a party or by which it is bound; and (y) upon the execution and
delivery of this Agreement by the Consultant, this Agreement shall be the valid and binding
obligation of the Company, enforceable in accordance with its terms.

 

 

 

10. Indemnification. The Company will indemnify (and advance the costs of defense of)
and hold harmless the Consultant (and his legal representatives) to the fullest extent permitted by
the laws of the state in which the Company is incorporated, as in effect at the time
of the subject act or omission, or by the Certificate of Incorporation and Bylaws of the
Company, as in effect at such time or on the date of this Agreement, whichever affords greater
protection to the Consultant, and the Consultant shall be entitled to the protection of any
insurance policies the Company may elect to maintain generally for the benefit of its executive
officers and directors, against all judgments, damages, liabilities, costs, charges and expenses
whatsoever incurred or sustained by him or his legal representative in connection with any action,
suit or proceeding to which he (or his legal representatives or other successors) may be made a
party by reason of his performing services under this Agreement or having been an officer or
director of the Company or any of its subsidiaries except that the Company shall have no obligation
to indemnify Consultant for liabilities resulting from conduct of the Consultant with respect to
which a court of competent jurisdiction has made a final determination that Consultant committed
gross negligence or willful misconduct to the extent such a determination was made by the court in
determining liability.

11. Entire Agreement. This Agreement sets forth the entire agreement and
understanding of the parties hereto with respect to the matters covered hereby and supersedes any
prior agreement or understanding, including without limitation the Employment Agreement, which is
as of the Effective Date terminated and of no further legal force or effect, provided that the
Company shall pay or provide the Consultant any accrued but unpaid compensation earned pursuant to
the Employment Agreement through the Effective Date (such as accrued and unpaid salary) and the
Employee’s vested benefits under Company employee benefit plans, programs, and policies other than
equity or cash incentive programs, in each case in accordance with the terms of such plans,
programs and policies and the Employment Agreement.

12. Successors; Binding Agreement. This Agreement shall inure to the benefit of and
be enforceable by the Consultant and by his personal or legal representatives, executors,
administrators, heirs, distributees, devisees and legatees and by the Company and its respective
successors and assigns.

13. Notices. All notices and other communications required or permitted under this
Agreement shall be in writing and shall be deemed to have been duly given when personally
delivered, when delivered by courier or overnight express service or five days after having been
sent by certified or registered mail, postage prepaid, addressed (x) if to the Consultant, to the
Consultant’s address set forth in the records of the Company, or if to the Company to Office of the
General Counsel, Isolagen, Inc., 405 Eagleview Blvd., Exton, Pennsylvania 19341 or (y) to such
other address as any party may have furnished to the other parties in writing in accordance
herewith, except that notices of change of address shall be effective only upon receipt thereof.

 

 

 

14. Governing Law. The interpretation, construction and performance of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State
of Pennsylvania without regard to any conflict of laws principles.

15. Severability. In case any one or more of the provisions or part of a provision
contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in
any respect in any jurisdiction, such invalidity, illegality or unenforceability shall be deemed
not to affect any other jurisdiction or any other provision or part of a provision of this
Agreement, nor shall such invalidity, illegality or unenforceability affect the validity, legality
or enforceability of this Agreement or any provision or provisions hereof in any other
jurisdiction; and this Agreement shall be reformed and construed in such jurisdiction as if such
provision or part of a provision held to be invalid or illegal or unenforceable had never been
contained herein and such provision or part reformed so that it would be valid, legal and
enforceable in such jurisdiction to the maximum extent possible. In furtherance and not in
limitation of the foregoing, the Company and the Consultant each intend that the covenants
contained in Sections 8 and 9 shall be deemed to be a series of separate covenants, one for each
and every state of the United States and any foreign country set forth therein. If, in any
judicial proceeding, a court shall refuse to enforce any of such separate covenants, then such
unenforceable covenants shall be deemed eliminated from the provisions hereof for the purpose of
such proceedings to the extent necessary to permit the remaining separate covenants to be enforced
in such proceedings. If, in any judicial proceeding, a court shall refuse to enforce any one or
more of such separate covenants because the total time, scope or area thereof is deemed to be
excessive or unreasonable, then it is the intent of the parties hereto that such covenants, which
would otherwise be unenforceable due to such excessive or unreasonable period of time, scope or
area, be enforced for such lesser period of time, scope or area as shall be deemed reasonable and
not excessive by such court.

16. Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be deemed to be an original and all of which together shall constitute one and the same
instrument.

17. Miscellaneous. No provision of this Agreement may be modified or waived unless
such modification or waiver is agreed to in writing and executed by the Consultant and by a duly
authorized officer of the Company. No waiver by any party hereto at any time of any breach by
another party hereto of, or failure to comply with, any condition or provision of this Agreement to
be performed or complied with by such other party shall be deemed a waiver of any similar or
dissimilar conditions or provisions at the same or at any prior or subsequent time. Failure by the
Consultant or the Company to insist upon strict compliance with any provision of this Agreement or
to assert any right which the Consultant or the Company may
have hereunder shall not be deemed to be a waiver of such provision or right or any other
provision of or right under this Agreement.

* * * remainder of page intentionally left blank * * *

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written.

	 	 	 	 	 
	 	FIBROCELL SCIENCE, INC.

 	 
	 	By: 	         /s/ Declan Daly
 	 
	 	 	Title: 	 	 
	 	 	 
	 	CONSULTANT

 	 
	 	/s/ Dr. Robert Langer, PhD
 	 
	 	DR. ROBERT LANGER, PhDExhibit 10.3

Exhibit 10.3

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

 

 

 

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	1. Purpose
	 	 	1	 
	2. Definitions
	 	 	1	 
	3. Administration
	 	 	3	 
	4. Grants
	 	 	3	 
	5. Shares Subject to the Plan
	 	 	4	 
	6. Eligibility for Participation
	 	 	4	 
	7. Options
	 	 	4	 
	8. Stock Units
	 	 	6	 
	9. Stock Awards
	 	 	7	 
	10. Stock Appreciation Rights and Other Stock-Based Awards
	 	 	7	 
	11. Qualified Performance-Based Compensation
	 	 	8	 
	12. Deferrals
	 	 	9	 
	13. Withholding of Taxes
	 	 	9	 
	14. Transferability of Grants
	 	 	10	 
	15. Consequences of a Change of Control
	 	 	10	 
	16. Requirements for Issuance of Shares
	 	 	10	 
	17. Amendment and Termination of the Plan
	 	 	11	 
	18. Miscellaneous
	 	 	11	 

EXHIBITS

A. FORM OF INCENTIVE OPTION GRANTS

B. FORM OF NONQUALIFIED OPTION GRANTS

C. FORM OF BOARD OF DIRECTORS GRANTS

 

i

 

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

1. Purpose and Objectives

The Fibrocell Science, Inc. 2009 Equity Incentive Plan (the “Plan”) is designed to align the
interests of (i) designated employees of Fibrocell Science, Inc. (the “Company”) and its
subsidiaries, (ii) non-employee members of the board of directors of the Company, and
(iii) consultants and key advisors of the Company and its subsidiaries with the interests of the
Company’s stockholders and to provide incentives for such persons to exert maximum efforts for the
success of the Company. By extending the opportunity to receive grants of stock options, stock
units, stock awards, stock appreciation rights and other stock-based awards, the Company believes
that the Plan will encourage the participants to contribute materially to the growth of the
Company, thereby benefiting the Company’s shareholders, and will align the economic interests of
the participants with those of the shareholders. The Plan may furthermore be expected to benefit
the Company and its stockholders by making it possible for the Company to attract and retain the
best available talent. The Plan shall be effective as of September 3, 2009.

2. Definitions

Whenever used in this Plan, the following terms will have the respective meanings set forth
below:

(a) “Board” means the Company’s Board of Directors.

(b) “Cause” means, except to the extent otherwise specified by the Committee, a finding
by the Committee of a Participant’s incompetence in the performance of duties, disloyalty,
dishonesty, theft, embezzlement, or unauthorized disclosure of customer lists, product
lines, processes or trade secrets of the Employer, individually or as an employee, partner,
associate, officer or director of any organization.

(c) “Change of Control” shall be deemed to have occurred if:

(i) Any “person” (as such term is used in sections 13(d) and 14(d) of the
Exchange Act) becomes a “beneficial owner” (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of securities of the Company representing
more than 50% of the voting power of the then outstanding securities of the Company;
provided that a Change of Control shall not be deemed to occur as a result of a
transaction in which the Company becomes a subsidiary of another corporation and in
which the shareholders of the Company, immediately prior to the transaction, will
beneficially own, immediately after the transaction, shares entitling such
shareholders to more than 50% of all votes to which all shareholders of the parent
corporation would be entitled in the election of directors;

(ii) The consummation of (i) a merger or consolidation of the Company with
another corporation where the shareholders of the Company, immediately prior to the
merger or consolidation, will not beneficially own, immediately after the merger or
consolidation, shares entitling such shareholders to more than 50% of all votes to
which all shareholders of the surviving corporation would be entitled in the
election of directors, (ii) a sale or other disposition of all or substantially all
of the assets of the Company, or (iii) a liquidation or dissolution of the Company;
or

(d) “Code” means the Internal Revenue Code of 1986, as amended.

(e) “Committee” means the Compensation Committee of the Board or another committee
appointed by the Board to administer the Plan, or in the absence of such committee, the
entire Board. Grants that are intended to be “qualified performance-based compensation”
under section 162(m) of the Code shall be made by a committee that consists of two or more
persons appointed by the Board, all of whom shall be “outside directors” as defined under
section 162(m) of the Code and related Treasury regulations.

 

 

 

(f) “Company” means Fibrocell Science, Inc. and any successor corporation.

(g) “Company Stock” means the common stock of the Company.

(h) “Consultant” means a consultant or advisor who performs services for the Employer
and who renders bona fide services to the Employer, if the services are not in connection
with the offer and sale of securities in a capital-raising transaction and the Consultant
does not directly or indirectly promote or maintain a market for the Employer’s securities.

(i) “Disability” means a Participant’s becoming disabled within the meaning of
section 22(e)(3) of the Code, within the meaning of the Employer’s long-term disability plan
applicable to the Participant, or as otherwise determined by the Committee.

(j) “Effective Date” of the Plan means September 3, 2009.

(k) “Employee” means an employee of the Employer (including an officer or director who
is also an employee).

(l) “Employer” means the Company and its subsidiaries.

(m) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

(n) “Exercise Price” means the per share price at which shares of Company Stock may be
purchased under an Option, as designated by the Committee.

(o) “Fair Market Value” of Company Stock means, unless the Committee determines
otherwise with respect to a particular Grant, (i) if the principal trading market for the
Company Stock is the NYSE Amex, the NASDAQ Global Market, the NASDAQ Capital Market or
another national securities exchange, the “closing transaction” price at which shares of
Company Stock are traded on such securities exchange on the relevant date or (if there were
no trades on that date) the latest preceding date upon which a sale was reported, (ii) if
the Company Stock is not principally traded on a national securities exchange, but is quoted
on the NASD OTC Bulletin Board (“OTCBB”) or the Pink Sheets, the last reported “closing
transaction” price of Company Stock on the relevant date, as reported by the OTCBB or Pink
Sheets, or, if not so reported, as reported in a customary financial reporting service, as
the Committee determines, or (iii) if the Company Stock is not publicly traded or, if
publicly traded, is not subject to reported closing transaction prices as set forth above,
the Fair Market Value per share shall be as determined by the Committee. Notwithstanding the
foregoing, for federal, state and local income tax purposes, the Fair Market Value may be
determined by the Committee in accordance with uniform and non-discriminatory standards
adopted by it from time to time.

(p) “Grant” means an Option, Stock Unit, Stock Award, SAR or Other Stock-Based Award
granted under the Plan.

(q) “Grant Agreement” means the written instrument that sets forth the terms and
conditions of a Grant, including all amendments thereto.

(r) “Incentive Stock Option” means an Option that is intended to meet the requirements
of an incentive stock option under section 422 of the Code.

(s) “Non-Employee Director” means a member of the Board who is not an employee of the
Employer.

(t) “Nonqualified Stock Option” means an Option that is not intended to be taxed as an
incentive stock option under section 422 of the Code.

 

2

 

(u) “Option” means an option to purchase shares of Company Stock, as described in
Section 7.

(v) “Other Stock-Based Award” means any Grant based on, measured by or payable in
Company Stock (other than a Grant described in Sections 7, 8 or 9 of the Plan), as described
in Section 10.

(w) “Participant” means an Employee, Consultant or Non-Employee Director designated by
the Committee to participate in the Plan.

(x) “Plan” means this Fibrocell Science, Inc. 2009 Equity Incentive Plan, as in effect
from time to time.

(y) “SAR” means a stock appreciation right as described in Section 10.

(z) “Stock Award” means an award of Company Stock as described in Section 9.

(aa) “Stock Unit” means an award of a phantom unit representing a share of Company
Stock, as described in Section 8.

3. Administration

(a) Committee. The Plan shall be administered and interpreted by the Committee. Ministerial
functions may be performed by an administrative committee comprised of Company employees appointed
by the Committee.

(b) Committee Authority. The Committee shall have the sole authority to (i) determine the
Participants to whom Grants shall be made under the Plan, (ii) determine the type, size and terms
and conditions of the Grants to be made to each such Participant, (iii) determine the time when the
grants will be made and the duration of any applicable exercise or restriction period, including
the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms and
conditions of any previously issued Grant, subject to the provisions of Section 17 below, and
(v) deal with any other matters arising under the Plan.

(c) Committee Determinations. The Committee shall have full power and express discretionary
authority to administer and interpret the Plan, to make factual determinations and to adopt or
amend such rules, regulations, agreements and instruments for implementing the Plan and for the
conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s
interpretations of the Plan and all determinations made by the Committee pursuant to the powers
vested in it hereunder shall be conclusive and binding on all persons having any interest in the
Plan or in any awards granted hereunder. All powers of the Committee shall be executed in its sole
discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the
objectives of the Plan and need not be uniform as to similarly situated Participants.

4. Grants

(a) Grants under the Plan may consist of Options as described in Section 7, Stock Units as
described in Section 8, Stock Awards as described in Section 9, and SARs or Other Stock-Based
Awards as described in Section 10. All Grants shall be subject to such terms and conditions as the
Committee deems appropriate and as are specified in writing by the Committee to the Participant in
the Grant Agreement.

(b) All Grants shall be made conditional upon the Participant’s acknowledgement, in writing or
by acceptance of the Grant, that all decisions and determinations of the Committee shall be final
and binding on the Participant, his or her beneficiaries and any other person having or claiming an
interest under such Grant. Grants under a particular Section of the Plan need not be uniform as
among the Participants.

 

3

 

5. Shares Subject to the Plan

(a) Shares Authorized. The aggregate number of shares of Company Stock that may be issued
under the Plan is 4,000,000 shares, subject to adjustment as described in subsection (d) below.

(b) Source of Shares; Share Counting. Shares issued under the Plan may be authorized but
unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased
by the Company on the open market for purposes of the Plan. If and to the extent Options and SARs
granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered
without having been exercised, and if and to the extent that any Stock Awards, Stock Units or Other
Stock-Based Awards are forfeited or terminated, or otherwise are not paid in full, the shares
reserved for such Grants shall again be available for purposes of the Plan.

(c) Grants. All Grants under the Plan shall be expressed in shares of Company Stock. All cash
payments shall equal the Fair Market Value of the shares of Company Stock to which the cash
payments relate.

(d) Adjustments. If there is any change in the number or kind of shares of Company Stock
outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or
combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation,
(iii) by reason of a reclassification or change in par value, or (iv) by reason of any other
extraordinary or unusual event affecting the outstanding Company Stock as a class without the
Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is
substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary
dividend or distribution, the maximum number of shares of Company Stock available for issuance
under the Plan, the maximum number of shares of Company Stock for which any individual may receive
Grants in any year, the number of shares covered by outstanding Grants, the kind of shares issued
and to be issued under the Plan, and the price per share or the applicable market value of such
Grants may be appropriately adjusted by the Committee to reflect any increase or decrease in the
number of, or change in the kind or value of, issued shares of Company Stock to preclude, to the
extent practicable, the enlargement or dilution of rights and benefits under such Grants; provided,
however, that any fractional shares resulting from such adjustment shall be eliminated. Any
adjustments determined by the Committee shall be final, binding and conclusive. To the extent that
any Grant is subject to section 409A of the Code, or becomes subject to section 409A of the Code as
a result of any adjustment made hereunder, such adjustment shall be made in compliance with section
409A of the Code.

6. Eligibility for Participation

(a) Eligible Persons. All Employees, Consultants and Non-Employee Directors shall be eligible
to participate in the Plan.

(b) Selection of Participants. The Committee shall select the Employees, Consultants and
Non-Employee Directors to receive Grants and shall determine the number of shares of Company Stock
subject to each Grant.

7. Options

(a) General Requirements. The Committee may grant Options to an Employee, Consultant or
Non-Employee Director upon such terms and conditions as the Committee deems appropriate under this
Section 7. The Committee shall determine the number of shares of Company Stock that will be subject
to each Grant of Options to Employees, Consultants and Non-Employee Directors.

(b) Type of Option, Price and Term

(i) The Committee may grant Incentive Stock Options or Nonqualified Stock Options or
any combination of the two, all in accordance with the terms and conditions set forth
herein. Incentive Stock Options may be granted only to Employees of the Company or its
parents or subsidiaries, as defined in section 424 of the Code. Nonqualified Stock Options
may be granted to Employees, Consultants or Non-Employee Directors.

 

4

 

(ii) The Exercise Price of Company Stock subject to an Option shall be determined by
the Committee; provided, however, that the Exercise Price for an Option (including Incentive
Stock Options or Nonqualified Stock Options) will be equal to, or greater than, the Fair
Market Value of a share of Company Stock on the date the Option is granted and further
provided that an Incentive Stock Option may not be granted to an Employee who, at the time
of grant, owns stock possessing more than 10% of the total combined voting power of all
classes of stock of the Company or any parent or subsidiary, as defined in section 424 of
the Code, unless the Exercise Price per share is not less than 110% of the Fair Market Value
of the Company Stock on the date of grant

(iii) The Committee shall determine the term of each Option, which shall not exceed ten
years from the date of grant. However, an Incentive Stock Option that is granted to an
Employee who, at the time of grant, owns stock possessing more than 10% of the total
combined voting power of all classes of stock of the Company or any parent or subsidiary, as
defined in section 424 of the Code, may not have a term that exceeds five years from the
date of grant.

(iv) To the extent the Company is unable to obtain shareholder approval of the Plan
within one year of the Effective Date, any Incentive Stock Options issued pursuant to the
Plan shall automatically be considered Nonqualified Stock Options, and to the extent a
holder of an Incentive Stock Option exercises his or her Incentive Stock Option prior to
such shareholder approval date, such exercised Option shall automatically be considered to
have been a Nonqualified Stock Option.

(c) Exercisability of Options.

(i) Options shall become exercisable in accordance with such terms and conditions as
may be determined by the Committee and specified in the Grant Agreement. The Committee may
accelerate the exercisability of any or all outstanding Options at any time for any reason.

(ii) The Committee may provide in a Grant Agreement that the Participant may elect to
exercise part or all of an Option before it otherwise has become exercisable. Any shares so
purchased shall be restricted shares and shall be subject to a repurchase right in favor of
the Company during a specified restriction period, with the repurchase price equal to the
lesser of (A) the Exercise Price or (B) the Fair Market Value of such shares at the time of
repurchase, or such other restrictions as the Committee deems appropriate. Notwithstanding
the foregoing, to the extent that an Option would otherwise be exempt from section 409A of
the Code, the Committee may only include such a provision in a Grant Agreement for such an
Option if the inclusion of such a provision will not cause that Option to become subject to
section 409A of the Code.

(iii) Options granted to persons who are non-exempt employees under the Fair Labor
Standards Act of 1938, as amended, may not be exercisable for at least six months after the
date of grant (except that such Options may become exercisable, as determined by the
Committee, upon the Participant’s death, Disability or retirement, or upon a Change of
Control or other circumstances permitted by applicable regulations).

(d) Termination of Employment or Service. Upon termination of employment or the services of a
Participant, an Option may only be exercised as follows:

(i) In the event that a Participant ceases to be employed by, or provide service to,
the Employer for any reason other than Disability, death, or termination for Cause, any
Option which is otherwise exercisable by the Participant shall terminate unless exercised
within three months after the date on which the Participant ceases to be employed by, or
provide service to, the Employer (or within such other period of time as may be specified by
the Committee), but in any event no later than the date of expiration of the Option term.
Except as otherwise provided by the Committee, any of the Participant’s Options that are not
otherwise exercisable as of the date on which the Participant ceases to be employed by, or
provide service to, the Employer shall terminate as of such date.

 

5

 

(ii) In the event the Participant ceases to be employed by, or provide service to, the
Employer on account of a termination for Cause by the Employer, any Option held by the
Participant shall terminate as of the date the Participant ceases to be employed by, or
provide service to, the Employer. In addition, notwithstanding any other provisions of this
Section 7, if the Committee determines that the Participant has engaged in conduct that
constitutes Cause at any time while the Participant is employed by, or providing service to,
the Employer or after the Participant’s termination of employment or service, any Option
held by the Participant shall immediately terminate and the Participant shall automatically
forfeit all shares underlying any exercised portion of an Option for which the Company has
not yet delivered the share certificates, upon refund by the Company of the Exercise Price
paid by the Participant for such shares. Upon any exercise of an Option, the Company may
withhold delivery of share certificates pending resolution of an inquiry that could lead to
a finding resulting in a forfeiture.

(iii) In the event the Participant ceases to be employed by, or provide service to, the
Employer on account of the Participant’s Disability, any Option which is otherwise
exercisable by the Participant shall terminate unless exercised within one year after the
date on which the Participant ceases to be employed by, or provide service to, the Employer
(or within such other period of time as may be specified by the Committee), but in any event
no later than the date of expiration of the Option term. Except as otherwise provided by the
Committee, any of the Participant’s Options which are not otherwise exercisable as of the
date on which the Participant ceases to be employed by, or provide service to, the Employer
shall terminate as of such date.

(iv) If the Participant dies while employed by, or providing service to, the Employer
or while an Option remains outstanding under Section 7(d)(i) or 7(d)(iii) above (or within
such other period of time as may be specified by the Committee), any Option that is
otherwise exercisable by the Participant shall terminate unless exercised within one year
after the date on which the Participant ceases to be employed by, or provide service to, the
Employer (or within such other period of time as may be specified by the Committee), but in
any event no later than the date of expiration of the Option term. Except as otherwise
provided by the Committee, any of the Participant’s Options that are not otherwise
exercisable as of the date on which the Participant ceases to be employed by, or provide
service to, the Employer shall terminate as of such date.

(e) Exercise of Options. A Participant may exercise an Option that has become exercisable, in
whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the
Exercise Price for the Option (i) in cash, (ii) if permitted by the Committee, by delivering shares
of Company Stock owned by the Participant and having a Fair Market Value on the date of exercise
equal to the Exercise Price or by attestation to ownership of shares of Company Stock having an
aggregate Fair Market Value on the date of exercise equal to the Exercise Price, (iii) by payment
through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve
Board, or (iv) by such other method as the Committee may approve. Shares of Company Stock used to
exercise an Option shall have been held by the Participant for the requisite period of time to
avoid adverse accounting consequences to the Company with respect to the Option. Payment for the
shares pursuant to the Option, and any required withholding taxes, must be received by the time
specified by the Committee depending on the type of payment being made, but in all cases prior to
the issuance of the Company Stock.

(f) Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the
aggregate Fair Market Value of the stock on the date of the grant with respect to which Incentive
Stock Options are exercisable for the first time by a Participant during any calendar year, under
the Plan or any other stock option plan of the Company or a parent or subsidiary, as defined in
section 424 of the Code, exceeds $100,000, then the Option, as to the excess, shall be treated as a
Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not
an Employee of the Company or a parent or subsidiary, as defined in section 424 of the Code.

8. Stock Units

(a) General Requirements. The Committee may grant Stock Units to an Employee, Consultant or
Non-Employee Director, upon such terms and conditions as the Committee deems appropriate under this
Section 8. Each Stock Unit shall represent the right of the Participant to receive a share of
Company Stock or an amount based on the
value of a share of Company Stock. All Stock Units shall be credited to bookkeeping accounts on the
Company’s records for purposes of the Plan.

 

6

 

(b) Terms of Stock Units. The Committee may grant Stock Units that are payable on terms and
conditions determined by the Committee, which may include payment based on achievement of
performance goals. Stock Units may be paid at the end of a specified vesting or performance period,
or payment may be deferred to a date authorized by the Committee. The Committee shall determine the
number of Stock Units to be granted and the requirements applicable to such Stock Units.

(c) Payment With Respect to Stock Units. Payment with respect to Stock Units shall be made in
cash, in Company Stock, or in a combination of the two, as determined by the Committee. The Grant
Agreement shall specify the maximum number of shares that can be issued under the Stock Units.

(d) Requirement of Employment or Service. The Committee shall determine in the Grant
Agreement under what circumstances a Participant may retain Stock Units after termination of the
Participant’s employment or service, and the circumstances under which Stock Units may be
forfeited.

9. Stock Awards

(a) General Requirements. The Committee may issue shares of Company Stock to an Employee,
Consultant or Non-Employee Director under a Stock Award, upon such terms and conditions as the
Committee deems appropriate under this Section 9. Shares of Company Stock issued pursuant to Stock
Awards may be issued for cash consideration or for no cash consideration, and subject to
restrictions or no restrictions, as determined by the Committee. The Committee may establish
conditions under which restrictions on Stock Awards shall lapse over a period of time or according
to such other criteria as the Committee deems appropriate, including restrictions based upon the
achievement of specific performance goals. The Committee shall determine the number of shares of
Company Stock to be issued pursuant to a Stock Award.

(b) Requirement of Employment or Service. The Committee shall determine in the Grant
Agreement under what circumstances a Participant may retain Stock Awards after termination of the
Participant’s employment or service, and the circumstances under which Stock Awards may be
forfeited.

(c) Restrictions on Transfer. While Stock Awards are subject to restrictions, a Participant
may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Stock Award except
upon death as described in Section 14(a). Each certificate for a share of a Stock Award shall
contain a legend giving appropriate notice of the restrictions in the Grant. The Participant shall
be entitled to have the legend removed when all restrictions on such shares have lapsed. The
Company may retain possession of any certificates for Stock Awards until all restrictions on such
shares have lapsed.

(d) Right to Vote and to Receive Dividends. The Committee shall determine to what extent, and
under what conditions, the Participant shall have the right to vote shares of Stock Awards and to
receive any dividends or other distributions paid on such shares during the restriction period.

10. Stock Appreciation Rights and Other Stock-Based Awards

(a) The Committee may grant SARs to an Employee, Non-Employee Director or Consultant
separately or in tandem with an Option. The following provisions are applicable to SARs:

(i) Base Amount. The Committee shall establish the base amount of the SAR at the time
the SAR is granted. The base amount of each SAR shall be equal to the per share Exercise
Price of the related Option or, if there is no related Option, an amount that is at least
equal to the Fair Market Value of a share of Company Stock as of the date of Grant of the
SAR.

 

7

 

(ii) Tandem SARs. The Committee may grant tandem SARs either at the time the Option is
granted or at any time thereafter while the Option remains outstanding; provided, however,
that, in the case of an Incentive Stock Option, SARs may be granted only at the date of the
grant of the Incentive Stock Option. In the case of tandem SARs, the number of SARs granted
to a Participant that shall be exercisable during a specified period shall not exceed the
number of shares of Company Stock that the Participant may purchase upon the exercise of the
related Option during such period. Upon the exercise of an Option, the SARs relating to the
Company Stock covered by such Option shall terminate. Upon the exercise of SARs, the related
Option shall terminate to the extent of an equal number of shares of Company Stock.

(iii) Exercisability. An SAR shall be exercisable during the period specified by the
Committee in the Grant Agreement and shall be subject to such vesting and other restrictions
as may be specified in the Grant Agreement. The Committee may grant SARs that are subject to
achievement of performance goals or other conditions. The Committee may accelerate the
exercisability of any or all outstanding SARs at any time for any reason. SARs may only be
exercised while the Participant is employed by, or providing service to, the Employer or
during the applicable period after termination of employment or service as described in
Section 7(d). A tandem SAR shall be exercisable only during the period when the Option to
which it is related is also exercisable.

(iv) Grants to Non-Exempt Employees. SARs granted to persons who are non-exempt
employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for
at least six months after the date of grant (except that such SARs may become exercisable,
as determined by the Committee, upon the Participant’s death, Disability or retirement, or
upon a Change of Control or other circumstances permitted by applicable regulations).

(v) Value of SARs. When a Participant exercises SARs, the Participant shall receive in
settlement of such SARs an amount equal to the value of the stock appreciation for the
number of SARs exercised. The stock appreciation for an SAR is the amount by which the Fair
Market Value of the underlying Company Stock on the date of exercise of the SAR exceeds the
base amount of the SAR as described in subsection (i).

(vi) Form of Payment. The Committee shall determine whether the stock appreciation for
an SAR shall be paid in the form of shares of Company Stock, cash or a combination of the
two. For purposes of calculating the number of shares of Company Stock to be received,
 shares of Company Stock shall be valued at their Fair Market Value on the date of exercise
of the SAR. If shares of Company Stock are to be received upon exercise of an SAR, cash
shall be delivered in lieu of any fractional share.

(b) Other Stock-Based Awards. The Committee may grant other awards not specified in Sections
7, 8 or 9 above that are based on or measured by Company Stock to Employees, Consultants and
Non-Employee Directors, on such terms and conditions as the Committee deems appropriate. Other
Stock-Based Awards may be granted subject to achievement of performance goals or other conditions
and may be payable in Company Stock or cash, or in a combination of the two, as determined by the
Committee in the Grant Agreement.

11. Qualified Performance-Based Compensation

(a) Designation as Qualified Performance-Based Compensation. The Committee may determine that
Stock Units, Stock Awards, SARs or Other Stock-Based Awards granted to an Employee shall be
considered “qualified performance-based compensation” under section 162(m) of the Code, in which
case the provisions of this Section 11 shall apply to such Grants. The Committee may also grant
Options under which the exercisability of the Options is subject to achievement of performance
goals as described in this Section 11 or otherwise.

 

8

 

(b) Performance Goals. When Grants are made under this Section 11, the Committee shall
establish in writing (i) the objective performance goals that must be met, (ii) the period during
which performance will be measured, (iii) the maximum amounts that may be paid if the performance
goals are met, and (iv) any other conditions that the Committee deems appropriate and consistent
with the requirements of section 162(m) of the Code for “qualified performance-based compensation.” The performance goals shall satisfy the requirements
for “qualified performance-based compensation,” including the requirement that the achievement of
the goals be substantially uncertain at the time they are established and that the performance
goals be established in such a way that a third party with knowledge of the relevant facts could
determine whether and to what extent the performance goals have been met. The Committee shall not
have discretion to increase the amount of compensation that is payable, but may reduce the amount
of compensation that is payable, pursuant to Grants identified by the Committee as “qualified
performance-based compensation.”

(c) Criteria Used for Objective Performance Goals. The Committee shall use objectively
determinable performance goals based on one or more of the following criteria: stock price,
earnings per share, price-earnings multiples, gross profit, net earnings, operating earnings,
revenue, revenue growth, number of days sales outstanding in accounts receivable, number of days of
cost of sales in inventory, productivity, margin, EBITDA (earnings before interest, taxes,
depreciation and amortization), net capital employed, return on assets, shareholder return, return
on equity, return on capital employed, growth in assets, unit volume, sales, cash flow, market
share, relative performance to a comparison group designated by the Committee, debt reduction,
market capitalization or strategic business criteria consisting of one or more objectives based on
meeting specified R&D programs, new product releases, revenue goals, market penetration goals,
customer growth, geographic business expansion goals, cost targets, quality improvements, cycle
time reductions, manufacturing improvements and/or efficiencies, human resource programs, customer
programs, goals relating to acquisitions or divestitures or goals relating to FDA or other
regulatory approvals. The performance goals may relate to one or more business units or the
performance of the Company as a whole, or any combination of the foregoing. Performance goals need
not be uniform as among Participants. Performance goals may be set on a pre tax or after tax basis,
may be defined by absolute or relative measures, and may be valued on a growth or fixed basis.

(d) Timing of Establishment of Goals. The Committee shall establish the performance goals in
writing either before the beginning of the performance period or during a period ending no later
than the earlier of (i) 90 days after the beginning of the performance period or (ii) the date on
which 25% of the performance period has been completed, or such other date as may be required or
permitted under applicable regulations under section 162(m) of the Code.

(e) Certification of Results. The Committee shall certify the performance results for the
performance period specified in the Grant Agreement after the performance period ends. The
Committee shall determine the amount, if any, to be paid pursuant to each Grant based on the
achievement of the performance goals and the satisfaction of all other terms of the Grant
Agreement.

(f) Death, Disability or Other Circumstances. The Committee may provide in the Grant
Agreement that Grants under this Section 11 shall be payable, in whole or in part, in the event of
the Participant’s death or Disability, a Change of Control or under other circumstances consistent
with the Treasury regulations and rulings under section 162(m) of the Code.

12. Deferrals

The Committee may permit or require a Participant to defer receipt of the payment of cash or
the delivery of shares that would otherwise be due to the Participant in connection with any Grant.
The Committee shall establish rules and procedures for any such deferrals, consistent with
applicable requirements of section 409A of the Code.

13. Withholding of Taxes

(a) Required Withholding. All Grants under the Plan shall be subject to applicable federal
(including FICA), state and local tax withholding requirements. The Company may require that the
Participant or other person receiving or exercising Grants pay to the Company the amount of any
federal, state or local taxes that the Company is required to withhold with respect to such Grants,
or the Company may deduct from other wages paid by the Company the amount of any withholding taxes
due with respect to such Grants.

 

9

 

(b) Election to Withhold Shares. If the Committee so permits, a Participant may elect to
satisfy the Company’s tax withholding obligation with respect to Grants paid in Company Stock by having shares
withheld, at the time such Grants become taxable, up to an amount that does not exceed the minimum
applicable withholding tax rate for federal (including FICA), state and local tax liabilities. The
election must be in a form and manner prescribed by the Committee.

14. Transferability of Grants

(a) Restrictions on Transfer. Except as described in subsection (b) below, only the
Participant may exercise rights under a Grant during the Participant’s lifetime, and a Participant
may not transfer those rights except by will or by the laws of descent and distribution. When a
Participant dies, the personal representative or other person entitled to succeed to the rights of
the Participant may exercise such rights. Any such successor must furnish proof satisfactory to the
Company of his or her right to receive the Grant under the Participant’s will or under the
applicable laws of descent and distribution.

(b) Transfer of Nonqualified Stock Options to or for Family Members. Notwithstanding the
foregoing, the Committee may provide, in a Grant Agreement, that a Participant may transfer
Nonqualified Stock Options to family members, or one or more trusts or other entities for the
benefit of or owned by family members, consistent with the applicable securities laws, according to
such terms as the Committee may determine; provided that the Participant receives no consideration
for the transfer of an Option and the transferred Option shall continue to be subject to the same
terms and conditions as were applicable to the Option immediately before the transfer.

15. Consequences of a Change of Control

In the event of a Change of Control, the Committee may take any one or more of the following
actions with respect to any or all outstanding Grants, without the consent of any Participant:
(i) the Committee may determine that outstanding Options and SARs shall be fully exercisable, and
restrictions on outstanding Stock Awards and Stock Units shall lapse, as of the date of the Change
of Control or at such other time or subject to specific conditions as the Committee determines,
(ii) the Committee may require that Participants surrender their outstanding Options and SARs in
exchange for one or more payments by the Company, in cash or Company Stock as determined by the
Committee, in an amount equal to the amount by which the then Fair Market Value of the shares of
Company Stock subject to the Participant’s unexercised Options and SARs exceeds the Exercise Price,
if any, and on such terms as the Committee determines, (iii) after giving Participants an
opportunity to exercise their outstanding Options and SARs, the Committee may terminate any or all
unexercised Options and SARs at such time as the Committee deems appropriate, (iv) with respect to
Participants holding Stock Units or Other Stock-Based Awards, the Committee may determine that such
Participants shall receive one or more payments in settlement of such Stock Units or Other
Stock-Based Awards, in such amount and form and on such terms as may be determined by the
Committee, or (v) the Committee may determine that Grants that remain outstanding after the Change
of Control shall be converted to similar grants of the surviving corporation (or a parent or
subsidiary of the surviving corporation). Such acceleration, surrender, termination, settlement or
assumption shall take place as of the date of the Change of Control or such other date as the
Committee may specify. Notwithstanding the foregoing, to the extent required to comply with
section 409A of the Code, a Grant Agreement will include a definition of “Change of Control” that
complies with and falls within the definition of “change in control event” set forth in section
409A of the Code and any Internal Revenue Service regulations or other guidance issued thereunder.

16. Requirements for Issuance of Shares

No Company Stock shall be issued in connection with any Grant hereunder unless and until all
legal requirements applicable to the issuance of such Company Stock have been complied with to the
satisfaction of the Committee. The Committee shall have the right to condition any Grant made to
any Participant hereunder on such Participant’s undertaking in writing to comply with such
restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee
shall deem necessary or advisable, and certificates representing such shares may be legended to
reflect any such restrictions. Certificates representing shares of Company Stock issued under the
Plan will be subject to such stop-transfer orders and other restrictions as may be required by
applicable laws, regulations and
interpretations, including any requirement that a legend be placed thereon. No Participant shall
have any right as a shareholder with respect to Company Stock covered by a Grant until shares have
been issued to the Participant.

 

10

 

17. Amendment and Termination of the Plan

(a) Amendment. The Board may amend or terminate the Plan at any time; provided, however, that
the Board shall not amend the Plan without approval of the shareholders of the Company if such
approval is required in order to comply with the Code or applicable laws, or to comply with
applicable stock exchange requirements. No amendment or termination of this Plan shall, without the
consent of the Participant, materially impair any rights or obligations under any Grant previously
made to the Participant under the Plan, unless such right has been reserved in the Plan or the
Grant Agreement, or except as provided in Section 18(b) below. Notwithstanding anything in the Plan
to the contrary, the Board may amend the Plan in such manner as it deems appropriate in the event
of a change in applicable law or regulations.

(b) Shareholder Approval for “Qualified Performance-Based Compensation.” If Grants are made
under Section 11 above, the Plan must be reapproved by the Company’s shareholders no later than the
first shareholders meeting that occurs in the fifth year following the year in which the
shareholders previously approved the provisions of Section 11, if additional Grants are to be made
under Section 11 and if required by section 162(m) of the Code or the regulations thereunder.

(c) Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth
anniversary of its Effective Date, unless the Plan is terminated earlier by the Board or is
extended by the Board with the approval of the shareholders. The termination of the Plan shall not
impair the power and authority of the Committee with respect to an outstanding Grant.

18. Miscellaneous

(a) Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in this
Plan shall be construed to (i) limit the right of the Committee to make Grants under this Plan in
connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the
business or assets of any corporation, firm or association, including Grants to employees thereof
who become Employees, or for other proper corporate purposes, or (ii) limit the right of the
Company to grant stock options or make other stock-based awards outside of this Plan. Without
limiting the foregoing, the Committee may make a Grant to an employee of another corporation who
becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or
property, reorganization or liquidation involving the Company in substitution for a grant made by
such corporation. The terms and conditions of the Grants may vary from the terms and conditions
required by the Plan and from those of the substituted stock incentives, as determined by the
Committee

(b) Compliance with Law. The Plan, the exercise of Options and the obligations of the Company
to issue or transfer shares of Company Stock under Grants shall be subject to all applicable laws
and to approvals by any governmental or regulatory agency as may be required. With respect to
persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan
and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its
successors under the Exchange Act. In addition, it is the intent of the Company that Incentive
Stock Options comply with the applicable provisions of section 422 of the Code, that Grants of
“qualified performance-based compensation” comply with the applicable provisions of section 162(m)
of the Code and that, to the extent applicable, Grants comply with the requirements of section 409A
of the Code. To the extent that any legal requirement of section 16 of the Exchange Act or
section 422, 162(m) or 409A of the Code as set forth in the Plan ceases to be required under
section 16 of the Exchange Act or section 422, 162(m) or 409A of the Code, that Plan provision
shall cease to apply. The Committee may revoke any Grant if it is contrary to law or modify a Grant
to bring it into compliance with any valid and mandatory government regulation. The Committee may
also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may,
in its sole discretion, agree to limit its authority under this Section.

 

11

 

(c) Enforceability. The Plan shall be binding upon and enforceable against the Company and
its successors and assigns.

(d) Funding of the Plan; Limitation on Rights. This Plan shall be unfunded. The Company shall
not be required to establish any special or separate fund or to make any other segregation of
assets to assure the payment of any Grants under this Plan. Nothing contained in the Plan and no
action taken pursuant hereto shall create or be construed to create a fiduciary relationship
between the Company and any Participant or any other person. No Participant or any other person
shall under any circumstances acquire any property interest in any specific assets of the Company.
To the extent that any person acquires a right to receive payment from the Company hereunder, such
right shall be no greater than the right of any unsecured general creditor of the Company.

(e) Rights of Participants. Nothing in this Plan shall entitle any Employee, Non-Employee
Director or other person to any claim or right to receive a Grant under this Plan. Neither this
Plan nor any action taken hereunder shall be construed as giving any individual any rights to be
retained by or in the employment or service of the Employer.

(f) No Fractional Shares. No fractional shares of Company Stock shall be issued or delivered
pursuant to the Plan or any Grant. The Committee shall determine whether cash, other awards or
other property shall be issued or paid in lieu of such fractional shares or whether such fractional
shares or any rights thereto shall be forfeited or otherwise eliminated.

(g) Employees Subject to Taxation Outside the United States. With respect to Participants who
are subject to taxation in countries other than the United States, the Committee may make Grants on
such terms and conditions as the Committee deems appropriate to comply with the laws of the
applicable countries, and the Committee may create such procedures, addenda and subplans and make
such modifications as may be necessary or advisable to comply with such laws.

(h) Governing Law. The validity, construction, interpretation and effect of the Plan and
Grant Agreements issued under the Plan shall be governed and construed by and determined in
accordance with the laws of the State of Delaware, without giving effect to the conflict of laws
provisions thereof.

 

12

 

FORM OF INCENTIVE OPTION GRANTS

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

INCENTIVE STOCK OPTION GRANT

This STOCK OPTION GRANT, dated as of                     , (the “Date of Grant”), is delivered by
Fibrocell Science, Inc. (the “Company”) to                      (the “Grantee”).

RECITALS

The Fibrocell Science, Inc. 2009 Equity Incentive Plan (the “Plan”) provides for the grant of
options to purchase shares of common stock of the Company. The Compensation Committee of the
Committee of Directors of the Company, or if no such entity exists, the entire Board of Directors
(the “Committee”) has decided to make a stock option grant as an inducement for the Grantee to
promote the best interests of the Company and its shareholders.

To the extent the Company is unable to obtain shareholder approval of the Plan within one year
of the Effective Date, any Incentive Stock Options issued pursuant to the Plan shall automatically
be considered Nonqualified Stock Options, and to the extent a holder of an Incentive Stock Option
exercises his or her Incentive Stock Option prior to such shareholder approval date, such exercised
Option shall automatically be considered to have been a Nonqualified
Stock Option.

NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as
follows:

1. Grant of Option.

(a) Subject to the terms and conditions set forth in this Agreement and in the Plan, the
Company hereby grants to the Grantee an incentive stock option (the “Option”) to purchase
 _____ shares of common stock of the Company
(“Shares”) at an exercise price of $_______ per Share. The
Option shall become exercisable according to Paragraph 2 below.

(b) The Option is designated as an incentive stock option, as described in Paragraph 5 below.
However, if and to the extent the Option exceeds the limits for an incentive stock option, as
described in Paragraph 5, the Option shall be a nonqualified stock option.

2. Exercisability of Option. The Option shall become exercisable on the following dates,
if the Grantee is employed by, or providing service to, the Employer (as defined in the Plan) on
the applicable date:

	 	 	 
	Date	 	Shares for Which the Option is Exercisable
	 
	 	 
	 
	 	 
	 	 	 
	 
	 	 
	 	 	 
	 
	 	 
	 	 	 
	 
	 	 

The exercisability of the Option is cumulative, but shall not exceed 100% of the Shares subject to
the Option. If the foregoing schedule would produce fractional Shares, the number of Shares for
which the Option becomes exercisable shall be rounded down to the nearest whole Share.

 

 

 

3. Term of Option.

(a) The Option shall have a term of
 _____ 

years from the Date of Grant and shall terminate at
the expiration of that period, unless it is terminated at an earlier date pursuant to the
provisions of this Agreement or the Plan.

(b) The Option shall automatically terminate upon the happening of the first of the following
events:

(i) The expiration of the three-month period after the Grantee ceases to be employed
by, or provide service to, the Employer, if the termination is for any reason other than
Disability (as defined in the Plan), death or Cause (as defined in the Plan).

(ii) The expiration of the one-year period after the Grantee ceases to be employed by,
or provide service to, the Employer on account of the Grantee’s Disability.

(iii) The expiration of the one-year period after the Grantee ceases to be employed by,
or provide service to, the Employer, if the Grantee dies while employed by, or providing
service to, the Employer or while the Option remains outstanding as described in
subparagraph (i) or (ii) above.

(iv) The date on which the Grantee ceases to be employed by, or provide service to, the
Employer for Cause. In addition, notwithstanding the prior provisions of this Paragraph 3,
if the Grantee engages in conduct that constitutes Cause after the Grantee’s employment or
service terminates, the Option shall immediately terminate.

Notwithstanding the foregoing, in no event may the Option be exercised after the date that is
immediately before the
 _____ 

anniversary of the Date of Grant. Any portion of the Option that is
not exercisable at the time the Grantee ceases to be employed by, or provide service to, the
Employer shall immediately terminate.

4. Exercise Procedures.

(a) Subject to the provisions of Paragraphs 2 and 3 above, the Grantee may exercise part or
all of the exercisable Option by giving the Company written notice of intent to exercise in the
manner provided in this Agreement, specifying the number of Shares as to which the Option is to be
exercised and the method of payment. Payment of the exercise price shall be made in accordance
with procedures established by the Committee from time to time based on type of payment being made
but, in any event, prior to issuance of the Shares. The Grantee shall pay the exercise price (i)
in cash, (ii) with the approval of the Committee, by delivering Shares of the Company, which shall
be valued at their fair market value on the date of delivery, or by attestation (on a form
prescribed by the Committee) to ownership of Shares having a fair market value on the date of
exercise equal to the exercise price, (iii) by payment through a broker in accordance with
procedures permitted by Regulation T of the Federal Reserve Board or (iv) by such other method as
the Committee may approve. The Committee may impose from time to time such limitations as it deems
appropriate on the use of Shares of the Company to exercise the Option.

(b) The obligation of the Company to deliver Shares upon exercise of the Option shall be
subject to all applicable laws, rules, and regulations and such approvals by governmental agencies
as may be deemed appropriate by the Committee, including such actions as Company counsel shall deem
necessary or appropriate to comply with relevant securities laws and regulations. The Company may
require that the Grantee (or other person exercising the Option after the Grantee’s death)
represent that the Grantee is purchasing Shares for the Grantee’s own account and not with a view
to or for sale in connection with any distribution of the Shares, or such other representation as
the Committee deems appropriate.

(c) All obligations of the Company under this Agreement shall be subject to the rights of the
Company as set forth in the Plan to withhold amounts required to be withheld for any taxes, if
applicable. Subject to Committee approval, the Grantee may elect to satisfy any tax withholding
obligation of the Employer with respect to the Option by having Shares withheld up to an amount
that does not exceed the minimum applicable withholding tax rate for federal (including FICA),
state and local tax liabilities.

 

-2-

 

5. Designation as Incentive Stock Option.

(a) This Option is designated an incentive stock option under Section 422 of the Internal
Revenue Code of 1986, as amended (the “Code”). If the aggregate fair market value of the stock on
the date of the grant with respect to which incentive stock options are exercisable for the first
time by the Grantee during any calendar year, under the Plan or any other stock option plan of the
Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be
treated as a nonqualified stock option that does not meet the requirements of Section 422. If and
to the extent that the Option fails to qualify as an incentive stock option under the Code, the
Option shall remain outstanding according to its terms as a nonqualified stock option.

(b) The Grantee understands that favorable incentive stock option tax treatment is available
only if the Option is exercised while the Grantee is an employee of the Company or a parent or
subsidiary of the Company or within a period of time specified in the Code after the Grantee ceases
to be an employee. The Grantee understands that the Grantee is responsible for the income tax
consequences of the Option, and, among other tax consequences, the Grantee understands that he or
she may be subject to the alternative minimum tax under the Code in the year in which the Option is
exercised. The Grantee will consult with his or her tax adviser regarding the tax consequences of
the Option.

(c) The Grantee agrees that the Grantee shall immediately notify the Company in writing if the
Grantee sells or otherwise disposes of any Shares acquired upon the exercise of the Option and such
sale or other disposition occurs on or before the later of (i) two years after the Date of Grant or
(ii) one year after the exercise of the Option. The Grantee also agrees to provide the Company
with any information requested by the Company with respect to such sale or other disposition.

6. Change of Control. The provisions of the Plan applicable to a Change of Control shall
apply to the Option, and, in the event of a Change of Control, the Committee may take such actions
as it deems appropriate pursuant to the Plan.

7. Restrictions on Exercise. Only the Grantee may exercise the Option during the Grantee’s
lifetime. After the Grantee’s death, the Option shall be exercisable (subject to the limitations
specified in the Plan) solely by the legal representatives of the Grantee, or by the person who
acquires the right to exercise the Option by will or by the laws of descent and distribution, to
the extent that the Option is exercisable pursuant to this Agreement.

8. Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of
which are incorporated herein by reference, and in all respects shall be interpreted in accordance
with the Plan. The grant and exercise of the Option are subject to interpretations, regulations
and determinations concerning the Plan established from time to time by the Committee in accordance
with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) rights
and obligations with respect to withholding taxes, (ii) the registration, qualification or listing
of the Shares, (iii) changes in capitalization of the Company and (iv) other requirements of
applicable law. The Committee shall have the authority to interpret and construe the Option
pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions
arising hereunder.

9. No Employment or Other Rights. The grant of the Option shall not confer upon the
Grantee any right to be retained by or in the employ or service of the Employer and shall not
interfere in any way with the right of the Employer to terminate the Grantee’s employment or
service at any time. The right of the Employer to terminate at will the Grantee’s employment or
service at any time for any reason is specifically reserved.

10. No Shareholder Rights. Neither the Grantee, nor any person entitled to exercise the
Grantee’s rights in the event of the Grantee’s death, shall have any of the rights and privileges
of a shareholder with respect to the Shares subject to the Option, until certificates for Shares
have been issued upon the exercise of the Option.

11. Assignment and Transfers. The rights and interests of the Grantee under this Agreement
may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of
the Grantee, by will or by the laws of descent and distribution. In the event of any attempt by
the Grantee to alienate, assign, pledge, hypothecate, or otherwise dispose of the Option or any
right hereunder, except as provided for in this Agreement, or in the event of the levy or any
attachment, execution or similar process upon the rights or interests hereby conferred, the Company
may terminate the Option by notice to the Grantee, and the Option and all rights hereunder shall
thereupon become null and void. The rights and protections of the Company hereunder shall extend
to any successors or assigns of the
Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned
by the Company without the Grantee’s consent.

 

-3-

 

12. Applicable Law. The validity, construction, interpretation and effect of this
instrument shall be governed by and construed in accordance with the laws of the State of Delaware,
without giving effect to the conflicts of laws provisions thereof.

13. Notice. Any notice to the Company provided for in this instrument shall be addressed
to the Company in care of the General Counsel at 405 Eagleview Blvd., Exton, PA 19341, and any
notice to the Grantee shall be addressed to such Grantee at the current address shown on the
payroll of the Employer, or to such other address as the Grantee may designate to the Employer in
writing. Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed
envelope addressed as stated above, registered and deposited, postage prepaid, in a post office
regularly maintained by the United States Postal Service.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

-4-

 

IN WITNESS WHEREOF, the Company has caused its duly authorized officers to execute and attest
this Agreement, and the Grantee has executed this Agreement, effective as of the Date of Grant.

	 	 	 	 	 	 	 
	 	 	FIBROCELL SCIENCE, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 

I hereby accept the Option described in this Agreement, and I agree to be bound by the terms of the
Plan and this Agreement. I hereby further agree that all the decisions and determinations of the
Committee shall be final and binding.

	 	 	 	 	 	 	 
	 

	 	Grantee:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 	 	 

 

-5-

 

FORM OF NONQUALIFIED OPTION GRANTS

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

NONQUALIFIED STOCK OPTION GRANT

This
STOCK OPTION GRANT, dated as of  ________ (the “Date of Grant”), is delivered by
Fibrocell Science, Inc. (the “Company”) to  ________ (the “Grantee”).

RECITALS

The Fibrocell Science, Inc. 2009 Equity Incentive Plan (the “Plan”) provides for the grant of
options to purchase shares of common stock of the Company. The Compensation Committee of the
Committee of Directors of the Company, or if no such entity exists, the entire Board of Directors
(the “Committee”) has decided to make a stock option grant as an inducement for the Grantee to
promote the best interests of the Company and its shareholders.

NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as
follows:

1. Grant of Option. Subject to the terms and conditions set forth in this Agreement and in
the Plan, the Company hereby grants to the Grantee a nonqualified stock option (the “Option”) to
purchase ________ shares of common stock of the Company (“Shares”) at an exercise price of
$________ per Share. The Option shall become exercisable according to Paragraph 2 below.

2. Exercisability of Option. The Option shall become exercisable on the following dates,
if the Grantee is employed by, or providing service to, the Employer (as defined in the Plan) on
the applicable date:

	 	 	 
	Date	 	Shares for Which the Option is Exercisable
	 
	 	 
	 	 	 
	 
	 	 
	 
	 	 

The exercisability of the Option is cumulative, but shall not exceed 100% of the Shares subject to
the Option. If the foregoing schedule would produce fractional Shares, the number of Shares for
which the Option becomes exercisable shall be rounded down to the nearest whole Share.

3. Term of Option.

(a) The
Option shall have a term of ________ years from the Date of Grant and shall terminate at
the expiration of that period, unless it is terminated at an earlier date pursuant to the
provisions of this Agreement or the Plan.

(b) The Option shall automatically terminate upon the happening of the first of the following
events:

(i) The expiration of the three-month period after the Grantee ceases to be employed
by, or provide service to, the Employer, if the termination is for any reason other than
Disability (as defined in the Plan), death or Cause (as defined in the Plan).

(ii) The expiration of the one-year period after the Grantee ceases to be employed by,
or provide service to, the Employer on account of the Grantee’s Disability.

 

 

 

(iii) The expiration of the one-year period after the Grantee ceases to be employed by,
or provide service to, the Employer, if the Grantee dies while employed by, or providing
service to, the Employer or while the Option remains outstanding as described in
subparagraph (i) or (ii) above.

(iv) The date on which the Grantee ceases to be employed by, or provide service to, the
Employer for Cause. In addition, notwithstanding the prior provisions of this Paragraph 3,
if the Grantee engages in conduct that constitutes Cause after the Grantee’s employment or
service terminates, the Option shall immediately terminate.

Notwithstanding the foregoing, in no event may the Option be exercised after the date that is
immediately before the                      anniversary of the Date of Grant. Any portion of the Option that
is not exercisable at the time the Grantee ceases to be employed by, or provide service to, the
Employer shall immediately terminate.

4. Exercise Procedures.

(a) Subject to the provisions of Paragraphs 2 and 3 above, the Grantee may exercise part or
all of the exercisable Option by giving the Company written notice of intent to exercise in the
manner provided in this Agreement, specifying the number of Shares as to which the Option is to be
exercised and the method of payment. Payment of the exercise price shall be made in accordance
with procedures established by the Committee from time to time based on type of payment being made
but, in any event, prior to issuance of the Shares. The Grantee shall pay the exercise price (i)
in cash, (ii) with the approval of the Committee, by delivering Shares of the Company, which shall
be valued at their fair market value on the date of delivery, or by attestation (on a form
prescribed by the Committee) to ownership of Shares having a fair market value on the date of
exercise equal to the exercise price, (iii) by payment through a broker in accordance with
procedures permitted by Regulation T of the Federal Reserve Board or (iv) by such other method as
the Committee may approve. The Committee may impose from time to time such limitations as it deems
appropriate on the use of Shares of the Company to exercise the Option.

(b) The obligation of the Company to deliver Shares upon exercise of the Option shall be
subject to all applicable laws, rules, and regulations and such approvals by governmental agencies
as may be deemed appropriate by the Committee, including such actions as Company counsel shall deem
necessary or appropriate to comply with relevant securities laws and regulations. The Company may
require that the Grantee (or other person exercising the Option after the Grantee’s death)
represent that the Grantee is purchasing Shares for the Grantee’s own account and not with a view
to or for sale in connection with any distribution of the Shares, or such other representation as
the Committee deems appropriate.

(c) All obligations of the Company under this Agreement shall be subject to the rights of the
Company as set forth in the Plan to withhold amounts required to be withheld for any taxes, if
applicable. Subject to Committee approval, the Grantee may elect to satisfy any tax withholding
obligation of the Employer with respect to the Option by having Shares withheld up to an amount
that does not exceed the minimum applicable withholding tax rate for federal (including FICA),
state and local tax liabilities.

5. Change of Control. The provisions of the Plan applicable to a Change of Control shall
apply to the Option, and, in the event of a Change of Control, the Committee may take such actions
as it deems appropriate pursuant to the Plan.

6. Restrictions on Exercise. Except as the Committee may otherwise permit pursuant to the
Plan, only the Grantee may exercise the Option during the Grantee’s lifetime and, after the
Grantee’s death, the Option shall be exercisable (subject to the limitations specified in the Plan)
solely by the legal representatives of the Grantee, or by the person who acquires the right to
exercise the Option by will or by the laws of descent and distribution, to the extent that the
Option is exercisable pursuant to this Agreement.

 

-2-

 

7. Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of
which are incorporated herein by reference, and in all respects shall be interpreted in accordance
with the Plan. The grant and exercise of the Option are subject to interpretations, regulations
and determinations concerning the Plan established from time to time by the Committee in accordance
with the provisions of the Plan, including, but not limited to,
provisions pertaining to (i) rights and obligations with respect to withholding taxes, (ii) the
registration, qualification or listing of the Shares, (iii) changes in capitalization of the
Company and (iv) other requirements of applicable law. The Committee shall have the authority to
interpret and construe the Option pursuant to the terms of the Plan, and its decisions shall be
conclusive as to any questions arising hereunder.

8. No Employment or Other Rights. The grant of the Option shall not confer upon the
Grantee any right to be retained by or in the employ or service of the Employer and shall not
interfere in any way with the right of the Employer to terminate the Grantee’s employment or
service at any time. The right of the Employer to terminate at will the Grantee’s employment or
service at any time for any reason is specifically reserved.

9. No Shareholder Rights. Neither the Grantee, nor any person entitled to exercise the
Grantee’s rights in the event of the Grantee’s death, shall have any of the rights and privileges
of a shareholder with respect to the Shares subject to the Option, until certificates for Shares
have been issued upon the exercise of the Option.

10. Assignment and Transfers. Except as the Committee may otherwise permit pursuant to the
Plan, the rights and interests of the Grantee under this Agreement may not be sold, assigned,
encumbered or otherwise transferred except, in the event of the death of the Grantee, by will or by
the laws of descent and distribution. In the event of any attempt by the Grantee to alienate,
assign, pledge, hypothecate, or otherwise dispose of the Option or any right hereunder, except as
provided for in this Agreement, or in the event of the levy or any attachment, execution or similar
process upon the rights or interests hereby conferred, the Company may terminate the Option by
notice to the Grantee, and the Option and all rights hereunder shall thereupon become null and
void. The rights and protections of the Company hereunder shall extend to any successors or
assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement
may be assigned by the Company without the Grantee’s consent.

11. Applicable Law. The validity, construction, interpretation and effect of this
instrument shall be governed by and construed in accordance with the laws of the State of Delaware,
without giving effect to the conflicts of laws provisions thereof.

12. Notice. Any notice to the Company provided for in this instrument shall be addressed
to the Company in care of the General Counsel at 405 Eagleview Blvd., Exton, PA 19341, and any
notice to the Grantee shall be addressed to such Grantee at the current address shown on the
payroll of the Employer, or to such other address as the Grantee may designate to the Employer in
writing. Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed
envelope addressed as stated above, registered and deposited, postage prepaid, in a post office
regularly maintained by the United States Postal Service.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

-3-

 

IN WITNESS WHEREOF, the Company has caused its duly authorized officers to execute and attest
this Agreement, and the Grantee has executed this Agreement, effective as of the Date of Grant.

	 	 	 	 	 
	 	FIBROCELL SCIENCE, INC.

 	 
	 	By:  	 	 

I hereby accept the Option described in this Agreement, and I agree to be bound by the terms of the
Plan and this Agreement. I hereby further agree that all the decisions and determinations of the
Committee shall be final and binding.

	 	 	 	 	 	 	 
	 

	 	Grantee:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

 

-4-

 

FORM OF BOARD OF DIRECTORS GRANTS

FIBROCELL SCIENCE, INC.

2009 EQUITY INCENTIVE PLAN

NONQUALIFIED STOCK OPTION GRANT

This STOCK OPTION GRANT, dated as of                                          (the “Date of Grant”), is delivered by
Fibrocell Science, Inc. (the “Company”) to                                          (the “Grantee”).

RECITALS

The Fibrocell Science, Inc. 2009 Equity Incentive Plan (the “Plan”) provides for the grant of
options to purchase shares of common stock of the Company. The Compensation Committee of the
Committee of Directors of the Company, or if no such entity exists, the entire Board of Directors
(the “Committee”) has decided to make a stock option grant as an inducement for the Grantee to
promote the best interests of the Company and its shareholders.

NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as
follows:

1. Grant of Option. Subject to the terms and conditions set forth in this Agreement and in
the Plan, the Company hereby grants to the Grantee a nonqualified stock option (the “Option”) to
purchase                      shares of common stock of the Company (“Shares”) at an exercise price of
$                     per Share. The Option shall become exercisable according to Paragraph 2 below.

2. Exercisability of Option. The Option shall become exercisable on the following dates,
if the Grantee is providing service to the Company as a member of its Board of Directors on the
applicable date:

	 	 	 
	Date	 	Shares for Which the Option is Exercisable
	 
	 	 
	 
	 	 
	 
	 	 
	 
	 	 

The exercisability of the Option is cumulative, but shall not exceed 100% of the Shares subject to
the Option. If the foregoing schedule would produce fractional Shares, the number of Shares for
which the Option becomes exercisable shall be rounded down to the nearest whole Share. Any portion
of the Option that is not exercisable at the time the Grantee ceases to be a member of the Board of
Directors shall immediately terminate.

3. Term of Option. The Option shall have a term of                      years from the Date of Grant and
shall terminate at the expiration of that period, unless it is terminated at an earlier date
pursuant to the provisions of this Agreement or the Plan. Notwithstanding anything to the contrary
in the Plan, the Option shall not terminate due to the termination of service, death, or Disability
of the Grantee.

4. Exercise Procedures.

(a) Subject to the provisions of Paragraphs 2 and 3 above, the Grantee may exercise part or
all of the exercisable Option by giving the Company written notice of intent to exercise in the
manner provided in this Agreement, specifying the number of Shares as to which the Option is to be
exercised and the method of payment. Payment of the exercise price shall be made in accordance
with procedures established by the Committee from time to time based on type of payment being made
but, in any event, prior to issuance of the Shares. The Grantee shall pay the exercise price (i)
in cash, (ii) with the approval of the Committee, by delivering Shares of the Company,
which shall be valued at their fair market value on the date of delivery, or by attestation
(on a form prescribed by the Committee) to ownership of Shares having a fair market value on the
date of exercise equal to the exercise price, (iii) by payment through a broker in accordance with
procedures permitted by Regulation T of the Federal Reserve Board or (iv) by such other method as
the Committee may approve. The Committee may impose from time to time such limitations as it deems
appropriate on the use of Shares of the Company to exercise the Option.

 

 

 

(b) The obligation of the Company to deliver Shares upon exercise of the Option shall be
subject to all applicable laws, rules, and regulations and such approvals by governmental agencies
as may be deemed appropriate by the Committee, including such actions as Company counsel shall deem
necessary or appropriate to comply with relevant securities laws and regulations. The Company may
require that the Grantee (or other person exercising the Option after the Grantee’s death)
represent that the Grantee is purchasing Shares for the Grantee’s own account and not with a view
to or for sale in connection with any distribution of the Shares, or such other representation as
the Committee deems appropriate.

(c) All obligations of the Company under this Agreement shall be subject to the rights of the
Company as set forth in the Plan to withhold amounts required to be withheld for any taxes, if
applicable. Subject to Committee approval, the Grantee may elect to satisfy any tax withholding
obligation of the Company with respect to the Option by having Shares withheld up to an amount that
does not exceed the minimum applicable withholding tax rate for federal (including FICA), state and
local tax liabilities.

5. Change of Control. The provisions of the Plan applicable to a Change of Control shall
apply to the Option, and, in the event of a Change of Control, the Committee may take such actions
as it deems appropriate pursuant to the Plan.

6. Restrictions on Exercise. Except as the Committee may otherwise permit pursuant to the
Plan, only the Grantee may exercise the Option during the Grantee’s lifetime and, after the
Grantee’s death, the Option shall be exercisable (subject to the limitations specified in the Plan)
solely by the legal representatives of the Grantee, or by the person who acquires the right to
exercise the Option by will or by the laws of descent and distribution, to the extent that the
Option is exercisable pursuant to this Agreement.

7. Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of
which are incorporated herein by reference, and in all respects shall be interpreted in accordance
with the Plan. The grant and exercise of the Option are subject to interpretations, regulations
and determinations concerning the Plan established from time to time by the Committee in accordance
with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) rights
and obligations with respect to withholding taxes, (ii) the registration, qualification or listing
of the Shares, (iii) changes in capitalization of the Company and (iv) other requirements of
applicable law. The Committee shall have the authority to interpret and construe the Option
pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions
arising hereunder.

8. No Service or Other Rights. The grant of the Option shall not confer upon the Grantee
any right to be retained by or in the service of the Company.

9. No Shareholder Rights. Neither the Grantee, nor any person entitled to exercise the
Grantee’s rights in the event of the Grantee’s death, shall have any of the rights and privileges
of a shareholder with respect to the Shares subject to the Option, until certificates for Shares
have been issued upon the exercise of the Option.

10. Assignment and Transfers. Except as the Committee may otherwise permit pursuant to the
Plan, the rights and interests of the Grantee under this Agreement may not be sold, assigned,
encumbered or otherwise transferred except, in the event of the death of the Grantee, by will or by
the laws of descent and distribution. In the event of any attempt by the Grantee to alienate,
assign, pledge, hypothecate, or otherwise dispose of the Option or any right hereunder, except as
provided for in this Agreement, or in the event of the levy or any attachment, execution or similar
process upon the rights or interests hereby conferred, the Company may terminate the Option by
notice to the Grantee, and the Option and all rights hereunder shall thereupon become null and
void. The rights and protections of the Company hereunder shall extend to any successors or
assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement
may be assigned by the Company without the Grantee’s consent.

 

-2-

 

11. Applicable Law. The validity, construction, interpretation and effect of this
instrument shall be governed by and construed in accordance with the laws of the State of Delaware,
without giving effect to the conflicts of laws provisions thereof.

12. Notice. Any notice to the Company provided for in this instrument shall be addressed
to the Company in care of the General Counsel at 405 Eagleview Blvd., Exton, PA 19341, and any
notice to the Grantee shall be addressed to such Grantee at the current address shown on the books
and records of the Company, or to such other address as the Grantee may designate to the Company in
writing. Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed
envelope addressed as stated above, registered and deposited, postage prepaid, in a post office
regularly maintained by the United States Postal Service.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

-3-

 

IN WITNESS WHEREOF, the Company has caused its duly authorized officers to execute and attest
this Agreement, and the Grantee has executed this Agreement, effective as of the Date of Grant.

	 	 	 	 	 
	 	FIBROCELL SCIENCE, INC.

 	 
	 	By:  	 	 

I hereby accept the Option described in this Agreement, and I agree to be bound by the terms of the
Plan and this Agreement. I hereby further agree that all the decisions and determinations of the
Committee shall be final and binding.

	 	 	 	 	 	 	 
	 

	 	Grantee:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

 

-4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]